Authors
Latest:
CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to KnowThe emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.
Latest:
Dr. Deirdre Cohen on Emerging Agents in Gastric CancerDeirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.
Latest:
Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case ReportThis is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Latest:
Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLCDelvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.
Latest:
Demmie Aguilar on Selecting a Clinical Trial SiteDemmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.
Latest:
The Evolving Use of White Bagging in OncologyChannel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers.
Latest:
Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast CancerDenise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Latest:
No-Cost Counseling Can Address Psychosocial Needs of Patients With CancerCounseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.
Latest:
Dr. Aberle on Novel Approaches to Screening for Lung CancerDenise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.
Latest:
Improving Glycemic Control in Individuals With Cancer and DiabetesIt is estimated that 8%-18% of all cancer patients will have preexisting diabetes at the time they are diagnosed with cancer.
Latest:
Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral MetastasesDenise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.
Latest:
Hedgehog Signal Inhibition Hope or Hype?Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.
Latest:
Liquid Biopsy Technology Grows More Varied and Potentially More Useful in NSCLCThe definition of liquid biopsy has expanded to include the collection of cell-free DNA (cfDNA), along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of patients with cancer.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast CancerDennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.
Latest:
Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast CancerDennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Latest:
Dr. Scribner on the Role of Chemotherapy in Ovarian CancerDennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.
Latest:
Dennise Geiger Discusses Telephone Triage in Cancer CareDennise Geiger, RN, Regional Cancer Care Associates, Central Jersey Division, discusses difficulties nurses face when using telephone triage, and the plan that was developed to better streamline the process.Â
Latest:
Denosumab Wins Drug AwardAt the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.
Latest:
Dr. Sant'Angelo Explains Immunology Basics for OncologistsDerek Sant'Angelo, PhD, Division Chief, Developmental Biology, Robert Wood Johnson Medical School, Dept. of Pediatrics, discusses what medical oncologists need to understand about immunology.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Autophagy Modulation May Be a Novel Approach to Treatment of Advanced CancersAlthough prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.
Latest:
Bone-Targeted Therapies Evolve in Prostate CancerThe treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.
Latest:
Interdisciplinary Tumor Conferences: A Surgical Oncology Fellow's Review and PerspectiveDevin C. Flaherty, DO, PhD, a surgical oncology fellow, discusses the evolution of interdisciplinary tumor board conferences and remarks on why they are so beneficial to the care of patients with cancer.
Latest:
Combinations with Radiation for Head and Neck CancerDhanya K. Nambiar, PhD, Stanford University, discusses combinations with radiation therapy for patients with head and neck cancer.
Latest:
The Detection of Galectin-1 in Head and Neck CancerDhanya K. Nambiar, PhD, Stanford University, discusses the detection of Galectin-1 for patients with head and neck cancer.
Latest:
The Development of Galectin-1 for Head and Neck CancerDhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.
